Fewer Observations, Shift In Emphasis Seen In FDA's Pandemic-Reduced Inspections
US agency mostly saw less of the same when it scaled back inspectional activity during COVID-19, but observed more training and equipment issues.
You may also be interested in...
How The US FDA’s Inspectional Approach Is Shifting For The Post-Pandemic Era
Agency hints of a “hybrid” future of in-person inspections supplemented by alternative tools like remote interactive evaluations.
What To Do When Last Pandemic’s Answer To The Next Pandemic Falters: Point Fingers
US congressional ‘coronavirus crisis’ panel explores Emergent BioSolutions COVID-19 vaccine launch failures while scoring points about private sector support.
Emergent COVID-19 Vaccine Plant’s Quality Issues Draw Unusual Spotlight From US FDA Topsiders
Remediation must be quick and sure, say FDA’s Woodcock and Marks, despite challenges with facilities, equipment, processes and personnel training.